Tyme Technologies is a biotechnology company developing cancer metabolism-based therapies (CMBTs) that are intended to be effective across a range of solid tumors and hematologic cancers. Co.'s main clinical CMBT program, SM-88, is an oral investigational modified proprietary tyrosine derivative that is hypothesized to interrupt the metabolic processes of cancer cells by breaking down the cells' key defenses and leading to cell death through oxidative stress and exposure to the body's natural immune system. Co.'s TYME-18 is a CMBT compound under development that is delivered intratumorally. Like SM-88, TYME-18 utilizes the metabolism of cancer to create a treatment for inoperable tumors. The TYME stock yearly return is shown above.
The yearly return on the TYME stock yearly return page and across the coverage universe of our site,
is a measure of the annual return over the calendar year 2018 for the given stock.
When performing this calculation it is important to factor in dividends, because a financial instrument's annual return is
more than just the change in price if that instrument pays a dividend or coupon.
One way to factor dividends into the return is simply to count them as cash — we don't do
that here. Instead, our website aims to empower investors
by performing the TYME annual return calculation with any dividends reinvested as applicable (on ex-dates).
|